Experimental cell therapy for resistant lung cancer tested in tiny trial
NCT ID NCT05676749
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new treatment called C-TIL051 for people with advanced non-small cell lung cancer that no longer responded to standard immunotherapy. The treatment involved taking immune cells from the patient's tumor, growing them in a lab, and infusing them back along with two other drugs to boost their activity. Only one person was enrolled before the study was terminated, so we have very limited information on safety or effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- C-TIL051 (tumor-infiltrating lymphocytes) combined with NKTR-255 (IL-15) and pembrolizumab
- What this could lead to
- If it works, this could point toward a new treatment option for people with lung cancer that stopped responding to standard immunotherapy.
- What could go wrong
- This was a very early, small phase 1 trial that was terminated after only one participant. The approach is complex and risky, involving chemotherapy and multiple drugs, and may not prove effective or safe in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Allegheny Health Network-West Penn Hospital
Pittsburgh, Pennsylvania, 15224, United States
-
Duke Center for Cancer Immunotherapy
Raleigh, North Carolina, 27710, United States
-
Ochsner MD Anderson Cancer Center
New Orleans, Louisiana, 70121, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Can a pill outperform chemo for a Hard-to-Treat lung cancer mutation?
- Can a new drug shrink Hard-to-Treat tumors?
- Breath test may reveal who benefits from lung cancer immunotherapy
- Targeted radiation and immunotherapy join forces against Hard-to-Treat lung cancer
- Triple-Drug cocktail targets tough lung cancer mutations